Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5234690 | 0.99 | DPP4 (1.00) | DPP4 | |
| Water SCHEMBL465005 | 0.99 | DPP4 (0.96) | DPP4 | |
| Hydrochloric Acid SCHEMBL5236208 | 0.95 | DPP4 (1.00) | DPP4 | |
| Hydrochloric Acid SCHEMBL5234573 | 0.92 | DPP4 (0.87) | DPP4 | |
| Hydrochloric Acid SCHEMBL5238710 | 0.90 | DPP4 (0.98) | DPP4 | |
| Hydrochloric Acid SCHEMBL5236165 | 0.90 | DPP4 (0.83) | DPP4 | |
| Hydrochloric Acid SCHEMBL5239270 | 0.90 | DPP4 (0.83) | DPP4 | |
| Hydrochloric Acid SCHEMBL5235189 | 0.89 | DPP4 (0.82) | DPP4 | |
| SCHEMBL5238870 | 0.89 | DPP4 (0.78) | DPP4 | |
| SCHEMBL5238641 | 0.88 | DPP4 (0.77) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023095-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | Novartis AG (CH) | 2016-05-25 | — | — | EP | claimed |
| EP-2839832-A2 | Use of dipeptidyl peptidase IV inhibitors | Novartis AG (CH) | 2015-02-25 | — | — | EP | claimed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | claimed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | claimed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | claimed |
| EP-2165703-A2 | Direct compression formulation and process | Novartis Pharma AG. (CH) | 2010-03-24 | — | — | EP | claimed |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | BURKEY BRYAN | 2009-10-08 | — | — | US | claimed |
| EP-2079469-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090017015-A1 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | HUGHES THOMAS EDWARD | 2009-01-15 | — | — | US | claimed |
| US-20080300171-A1 | Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events | NOVARTIS AG (CH) | 2008-12-04 | — | — | US | claimed |
| EP-1686994-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| EP-1687030-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTI-OBESITY OR APPETITE REGULATING AGENT | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2006078593-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | claimed |
| WO-2006005613-A1 | COMBINATION OF DPP-IV INHIBITORS AND COMPOUNDS MODULATING 5-HT3 AND/OR 5-HT4 RECEPTORS | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | claimed |
| WO-2005079795-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | NOVARTIS AG (CH) | 2005-09-01 | — | — | WO | claimed |
| WO-2005067976-A2 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | claimed |
| WO-2005049022-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049088-A2 | COMBINATION OF A DPP IV INHIBITOR AND AN ANTIOBESITY OR APPETITE REGULATING AGENT | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885 |
| US-20090017015-A1 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | DPP4, DPP3, DPP7 | DPP4 1/4885 |
| US-20090253752-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN | PPARG, DPP4, DPP3 | DPP4 2/4885 |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | PPARG, DPP4, DPP3 | DPP4 2/4885 |
| US-20080300171-A1 | Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events | DPP4, DPP3, DPP7 | DPP4 1/4885 |
| US-20130052239-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.